Related Experiment Video

Updated: Aug 18, 2026

The Logic, Experimental Steps, and Potential of Heterologous Natural Product Biosynthesis Featuring the Complex Antibiotic Erythromycin A Produced Through E. coli
10:41

The Logic, Experimental Steps, and Potential of Heterologous Natural Product Biosynthesis Featuring the Complex Antibiotic Erythromycin A Produced Through E. coli

Published on: January 13, 2013

[Pharmacological availability of erythromycin granules for children's use]

S V Korenev, G B Garsheva, L Ia Nesterova

    Antibiotiki I Khimioterapiia = Antibiotics and Chemoterapy [Sic]
    |August 1, 1990
    PubMed

    Insights

    This study optimized erythromycin granules coating for pediatric use. A specific polymer blend ensures antibiotic protection in acidic environments, enhancing drug availability.

    Area of Science:

    • Pharmaceutical Sciences
    • Materials Science
    • Pediatric Pharmacology

    Background:

    • Erythromycin's pharmaceutical availability can be affected by gastric acid.
    • Pediatric formulations require careful consideration of drug stability and release.
    • Polymeric coatings offer a method to control drug release and protect sensitive antibiotics.

    Purpose of the Study:

    • To evaluate the pharmaceutical availability of erythromycin granules coated with various polymeric compositions.
    • To determine the optimal coating formulation for protecting erythromycin in acidic conditions.
    • To assess the impact of coating on the disintegration and dissolution profiles of erythromycin granules.

    Main Methods:

    • Coating erythromycin granules using acetylphthalyl cellulose in combination with hydroxypropyl methylcellulose or methyl cellulose.
    • Assessing coated granules based on disintegration time and dissolution rate in diverse media.
    • Analyzing the influence of polymer ratios on coating performance and drug protection.

    Main Results:

    • The combination of acetylphthalyl cellulose and hydroxypropyl methylcellulose (8:2 ratio) effectively protected erythromycin in acidic media.
    • This specific coating formulation demonstrated high pharmaceutical availability of the drug.
    • Coating significantly influenced the disintegration and dissolution characteristics of the erythromycin granules.

    Conclusions:

    • A polymeric coating of acetylphthalyl cellulose and hydroxypropyl methylcellulose (8:2) is suitable for enhancing erythromycin's pharmaceutical availability in pediatric formulations.
    • The developed coating protects the antibiotic from degradation in the stomach.
    • This formulation strategy can improve therapeutic outcomes for pediatric patients requiring erythromycin treatment.

    More Related Videos

    Identification of Pharmaceuticals in The Aquatic Environment Using HPLC-ESI-Q-TOF-MS and Elimination of Erythromycin Through Photo-Induced Degradation05:46

    Identification of Pharmaceuticals in The Aquatic Environment Using HPLC-ESI-Q-TOF-MS and Elimination of Erythromycin Through Photo-Induced Degradation

    Published on: August 1, 2018

    Disposable Dosators Intended for Dry Powder Delivery to Mice04:59

    Disposable Dosators Intended for Dry Powder Delivery to Mice

    Published on: August 18, 2023

    Related Concept Videos

    Factors Affecting Drug Response: Overview01:21

    Factors Affecting Drug Response: Overview

    When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
    Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

    Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

    Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
    Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

    Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

    Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
    Drug Dosing: Infants and Children01:29

    Drug Dosing: Infants and Children

    Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

    Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
    Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

    Pharmacokinetics in Pediatric Patients: Drug Distribution

    Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...